Blood phosphatidylethanol measurements indicate <scp>GLP</scp>‐1 receptor stimulation causes delayed decreases in alcohol consumption
This secondary analysis indicates that exenatide has a delayed yet significant impact on alcohol consumption in individuals with AUD and obesity, as assessed by PEth levels. These findings warrant further investigation, which is currently underway (NCT05895643).
Authors
- Anders Fink‐Jensen (ORCID: https://orcid.org/0000-0001-7143-1236)
- Tina Vilsbøll (ORCID: https://orcid.org/0000-0002-0456-6787)
- Mathias E. Jensen (ORCID: https://orcid.org/0000-0002-2555-4785)
- Gitte M. Knudsen (ORCID: https://orcid.org/0000-0003-1508-6866)
- M Bergmann (ORCID: https://orcid.org/0000-0001-9213-3676)
- Christophe Pol Stove (ORCID: https://orcid.org/0000-0001-7126-348X)
- Mette Kruse Klausen (ORCID: https://orcid.org/0000-0002-9300-470X)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- University of Southern Denmark (DK)
- Copenhagen Business School (DK)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Ghent University (BE)
- Region of Southern Denmark (DK)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1111/acer.70041
- Citations
- 5
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.97
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Novo Nordisk